APRIL BIO
April Bio is a drug development company that develops antibodies and long-acting biologics.
APRIL BIO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Chuncheon, Kangwon-do, South Korea
Country:
South Korea
Website Url:
http://www.aprilbio.com
Total Employee:
11+
Status:
Active
Contact:
+82 02 6956 8383
Total Funding:
53 B KRW
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apache Pound Sterling JQuery CDN Korea Telecom
Similar Organizations
Aimble
Aimble is an AI drug development company that offers drugs to treat intractable diseases.
Haihe Biopharma
Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.
ProAbTech
ProAbTech is a research and development company that develops conjugated biological drugs.
Toll Biotech
Toll Biotech is a drug research and development company that develops a series of small molecules for Toll-like receptor (TLR) targets.
Investors List
BNK Securities
BNK Securities investment in Series C - April Bio
Hana Financial Investment
Hana Financial Investment investment in Series C - April Bio
NH Investment & Securities
NH Investment & Securities investment in Series C - April Bio
Shinhan Asset Management
Shinhan Asset Management investment in Series C - April Bio
Baro Ventures
Baro Ventures investment in Series C - April Bio
Hana Securities
Hana Securities investment in Series C - April Bio
Premier Partners
Premier Partners investment in Series C - April Bio
DS Asset Management
DS Asset Management investment in Series C - April Bio
LB Investment
LB Investment investment in Series C - April Bio
DAOL Investment & Securities
DAOL Investment & Securities investment in Series C - April Bio
Official Site Inspections
http://www.aprilbio.com
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "April Bio"
April Bio - Crunchbase Company Profile & Funding
Organization. April Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. April Bio is a drug …See details»
APRILBIO
AprilBio, APB-A1 "The composition patent granted in the U.S." AprilBio (CEO, Sang-hoon CHA) announced on the 5th of October that the compound patent of APB-A1 (Lu AG22515, CD40L …See details»
APRILBIO
Aprilbio Co., LTD has built intimate networks for cooperation with leading enterprises and academic institutions in and out of Korea Please email us at [email protected] for partnering …See details»
AprilBio Co.,Ltd. Company Description - Stock Analysis
Oct 18, 2024 AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops products based on its long-acting protein medicine platform technology. It …See details»
AprilBio Company Profile 2024: Stock Performance
AprilBio General Information Description. AprilBio Co Ltd is a bio company is developing innovative biologis. It owns long acting protein medicine platform …See details»
AprilBio - Products, Competitors, Financials, Employees, …
AprilBio's products are designed to target inflammation and tumors effectively while minimizing side effects and immunogenicity. It was founded in 2013 and is based in Chuncheon, South …See details»
APRILBIO
Aprilbio develops diverse novel drugs based on its own albumin binder platform: SAFA™ Based on our human Fab antibody fragment technology, which specifically binds to serum albumin, …See details»
Aprilbio Co Ltd - VentureRadar
Aprilbio Co., Ltd. owns long-acting protein medicine platform technology utilizing human FAB antibody parts that makes unusual combination to serum albumin and EX-12 Helper Phage …See details»
AprilBio Co.,Ltd. (397030.KQ) Company Profile & Facts - Yahoo …
See the company profile for AprilBio Co.,Ltd. (397030.KQ) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
April Bio - Funding, Financials, Valuation & Investors - Crunchbase
April Bio is a drug development company that develops antibodies and long-acting biologics.See details»
AprilBio Co. Ltd. - BioCentury Company Profiles - BCIQ
Nov 7, 2023 AprilBio Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Lundbeck acquires exclusive rights to APB-A1 from AprilBio
Oct 22, 2021 Lundbeck has entered into a definitive agreement with AprilBio, a biopharmaceutical company based in South Korea. Under the agreement between the two …See details»
AprilBio - Overview, News & Similar companies | ZoomInfo.com
AprilBio contact info: Phone number: (804) 330-3353 Website: www.aprilbio.com What does AprilBio do? AprilBio Co Ltd is a company that operates in the Biotechnology industry. It …See details»
Evommune Secures Exclusive Rights to Develop and …
Jun 19, 2024 collaborate with them,” commented Dr. Sang-hoon Cha, CEO at AprilBio. About EVO301 A long-acting injectable therapeutic, EVO-301 is a fusion-protein that is designed to …See details»
Lundbeck on LinkedIn: AprilBio | 22 comments
We have entered into a definitive agreement with AprilBio Co, a biopharma company from South Korea. We will receive the exclusive worldwide rights to research, develop and commercialize …See details»
APRILBIO
History of APRILBIO. 2024. 1. Participated in Biotech Showcase USA; 6. Out-licensed APB-R3(autoinflammatory disease treatment) to US Evommune; 9. Unveiled Next-generation new …See details»
AprilBio licenses out autoimmune disease to US firm for $475 mil.
Jun 21, 2024 Local analyst increase target price for AprilBio. Korea Investment & Securities raised the target price of AprilBio, stating that the company will turn a profit solely through …See details»
Series C - April Bio - 2021-08-24 - Crunchbase
April Bio raised $21468989 on 2021-08-24 in Series C. Start Free Trial . Chrome ExtensionSee details»
APRILBIO
AprilBio, APB-A1 "The composition patent granted in the U.S." 2023.10.05 AprilBio (CEO, Sang-hoon CHA) announced on the 5th of October that the compound patent of APB-A1 (Lu …See details»
Aprilbio, Evommune strike $475M deal for autoinflammatory drug
Jun 25, 2024 Aprilbio Co. Ltd. saw its stock surge 30% June 20 after announcing a potential $475 million (₩655.88 billion) deal with Evommune Inc. for autoimmune disease drug …See details»